<DOC>
	<DOCNO>NCT01751152</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial ass clinical efficacy safety NNC0114-0006 subject active Crohn 's disease .</brief_summary>
	<brief_title>A Randomised , Double-blind , Placebo-controlled , Parallel-group Trial Assess Clinical Efficacy Safety NNC0114-0006 Subjects With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Moderately severely active Crohn 's disease , define Crohn 's disease activity index ( CDAI ) 220450 ( inclusive ) Visit 2 ( Day 0 , Dosing ) , evidence inflammation confirm Creactive protein ( CRP ) equal 10 mg/L endoscopic verification ( accord endoscopy image manual ) perform Visit 1 ( Day 28 7 , Screening ) Biologicna√Øve subject biologicexperienced treatment Crohn 's disease . Biologicexperienced subject eligible fail one market biologic therapy treatment Crohn 's disease due lack efficacy ( primary secondary efficacy failure ) Body mass index ( BMI ) equal 38.0 kg/m^2 Any follow : symptomatic bowel obstruction , short bowel syndrome , ileostomy colostomy , surgical bowel resection within 6 month prior randomisation , total colectomy subtotal colectomy le 20 cm colon remain , abscesses adequately treated History dysplasia colon Any active ongoing bacterial infection within 4 week prior randomisation , unless treat resolved appropriate therapy Any history serious recurrent infection require hospitalisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>